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shortcut though impairs the analysis in many different ways, limiting our full
understanding of the phenomenon being modelled and ultimately our ability to
accurately assess ‘value for money’ beyond the simple ‘average’. This paper ex-
plores the value of access to individual patient data for cost-effectiveness model-
ling, structuring the discussion of the topic around three interrelated questions.
First, what benefits can access to IPD bring to cost-effectiveness modelling? Sec-
ond, what are the challenges for the simultaneous statistically synthesis of AD plus
IPD to derive input parameters for a cost-effectiveness model? Third, what is the
value of access to IPD compared to AD for cost-effectiveness modelling? Using two
different case studies, the above questions will be addressed and discussed in the
context of the debate around CEA of individualised treatment decisions.
DISEASE-SPECIFIC STUDIES
GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies
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OBJECTIVES: When comparing combined therapy with peginterferon alpha-2a or
alpha-2b and ribavirin to treat chronic hepatitis C (CHC), the results of clinical
trials, observational studies, and meta-analyses have been inconsistent. Their ef-
fectiveness and tolerability were investigated using the nationwide database of
chronic hepatitis patients who received interferon therapy in Japan. METHODS:
The proportion with a sustained virologic response (SVR) and the dropout rate due
to adverse events (AEs) were compared between alpha-2a and alpha-2b. All pa-
tients also received ribavirin. Multivariate logistic regression was conducted with
adjustment for age, sex, platelet counts, ALT, viral load, genotype, and whether the
patient was treatment-naïve, which are associated with effectiveness and
tolerability. RESULTS: By December 2011, the database included 7820 patients. CHC
patients treated with either alpha-2a (n1737) or alpha-2b (n4495) were analyzed.
The mean (SD) age was 58.1 (10.4) years, and 3131 (50.2%) were female. In total, 2503
(41.0%) patients had a platelet count150x103, 2503 (40.5%) had ALT 60 IU/L, and
5765 (93.2%) had a high viral load. The numbers with genotype 1, 2, and 3 were 4291
(69.2%), 1838 (29.6%), and 76 (1.2%), respectively. Overall, 4434 (71.2%) patients were
treatment-naïve. SVR was achieved in 53.5% (95% CI: 51.1-55.9%) with alpha-2a and
61.6% (95% CI: 60.2-63.1%) with alpha-2b (p0.001). The dropout rate due to any AEs
was 10.3% (95%CI: 8.9-11.8%) and 9.3% (95%CI: 8.5-10.2%) for alpha-2a and alpha-2b,
respectively (p0.226). After adjustment for possible confounders, no differences
in effectiveness or tolerability were observed between the therapies, and the odds
ratio of alpha-2a for SVR was 0.97 (95% CI: 0.86-1.10), and its odds ratio for dropout
due to any AEs was 0.96 (95% CI: 0.79-1.17). There was no significant interaction of
genotype and therapy.CONCLUSIONS:Alpha-2a and alpha-2b in combination with
ribavirin showed comparable effectiveness and tolerability in clinical settings.
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OBJECTIVES: In addition to the pharmacological efficacy of infliximab therapy in
inflammatory bowel disease (IBD), it is also important to evaluate its impact on
other health outcomes, particularly in the rate of surgical interventions and hos-
pitalizations, which have high economic burden and are believed to represent a
marker of IBD severity. We aimed to estimate the impact of infliximab in these
outcomes in patients with IBD.METHODS: Systematic review and meta-analysis of
experimental (clinical trials) and observational studies comparing infliximab with
any other control group in IBD. Studies were identified by searching Medline and
Cochrane from inception to April 2012. Search results and studies characteristics
were assessed independently. Subgroup analyses were done according to IBD type:
Crohn disease (CD) and ulcerative colitis (UC). Pooled estimates were performed
separately for clinical trials and observational studies. Odds ratios (OR) and 95%
confidence intervals (CI) were derived by random-effects meta-analysis. Heteroge-
neity was assessed with I2 test. RESULTS: Nine trials and 9 observational studies
were included. Infliximab significantly decreased risk of gastrointestinal surgery in
experimental studies (OR 0.36; 95%CI: 0.18-0.71), both in DC (OR 0.25; 95%CI: 0.10-
0.63) and UC (OR 0:55; 95%CI: 0.40-0.76). In absolute terms, there was a 9% reduction
in the rate of surgery (95%CI: 1-19%). Observational studies also showed a reduced
risk of surgery, which was significant in the case of CD (OR 0.42; 95% CI: 0.22 to 0.78).
Infliximab significantly reduced the risk of hospitalization, both in experimental
(OR 0.48; 95%CI: 0.34-0.66) and observational (OR 0:38; 95%CI: 0.24-0.58) studies,
with a decrease of 9% in hospitalization rate (95%CI: 5-14%). Mean duration of
hospitalization was shorten by 4.2 days (95%CI: 1.9-6.5) in infliximab treated
patients. CONCLUSIONS: Based on the best available evidence, infliximab therapy
is associated with a reduced risk of gastrointestinal surgery and hospitalization
rates in patients with IBD.
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OBJECTIVES: To describe health outcomes, the course of treatment and the
demographic and clinical characteristics of HCV adult patients infected with
genotype 1 receiving interferon-alfaribavirin therapy in Poland. METHODS: A
retrospective analysis of anonymous data of patients treated in the HCV thera-
peutic programme of the National Health Fund was performed. Data was gath-
ered from three medical centres and included demographic and clinical char-
acteristics (sex, age, body weight, initial HCV RNA level, disease staging and
grading) as well as treatment course (first line/retreatment, posology, treatment
duration, outcomes and discontinuations). RESULTS: A total of 813 HCV geno-
type 1 adult patients’ records [586 treatment-naïve (N) and 227 treatment-expe-
rienced (E)] were included in the analysis. 55% were male (N: 53%, E: 60%), mean
age at the beginning of therapy was 48 (SD:13) years. Mean body weight was 68,0
(SD:11,8) kg in females and 82,4 (SD:12,3) kg in males. Mean initial HCV RNA was
5,9 (SD:0,8) log10IU/mL and 46% of patients had HCV RNA800 000 IU/mL. A total
of 85% records included data on disease staging (Sheuer 0-2: 67%; stage 3: 19%;
stage 4: 14%). 96% of patients received pegylated interferons (pegylated inter-
feron-alfa2a: 54%), 97% with ribavirin. A total of 15% of patients discontinued
therapy prematurely (N: 14%, E: 18%) after a mean of 6 months, and mean
treatment duration was 44 weeks for all patients. Overall SVR (sustained viral
response) was achieved in 42% of patients (N: 45%, E: 33%). Among treatment-
naïve patients not fully responding to therapy, 41% had relapse, 21% were par-
tial responders and 38% were null-responders. CONCLUSIONS: The real-life re-
sults of HCV genotype 1 treatment, with SVR rates below 50% in treatment naïve
patients, are unsatisfactory, especially when in Poland the prevalence of this
difficult-to-treat genotype is one of the most highest in Europe. Forthcoming
triple therapy with HCV protease inhibitors are promising and anticipated op-
tions for these patients.
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OBJECTIVES: This meta-analysis of randomized controlled trials was conducted to
evaluate the efficacy and incontinence rate of biomaterials (fibrin glue and fibrin
plug) in comparison to conservative and other interventional therapy in the treat-
ment of perianal fistula. METHODS: PubMed, Embase, Scopus, Google Scholar, and
Web of Science were searched for clinical trial studies investigated the effects of
biomaterials in the treatment of fistul in-ano. Clinical response and incontinence
were the key outcomes of interest. Data were searched from the time period of 1966
through June 2012. RESULTS: Eight randomized placebo-controlled clinical trials
that met our criteria (six comparing biomaterial with conservative treatment and
two with other interventions) were included in the analysis. Pooling of data showed
biomaterials effectiveness in comparison to other interventions was non signifi-
cant with relative risk (RR) of 1.23 (95% CI of 0.31-4.84, P 0.77). The RR for bioma-
terials comparing with conservative was non significant (RR 0.73 with 95% CI 
0.31-0.89, P 0.096). The incontinence rate RR in biomaterials and intervention was
also non significant with RR of 0.35 (95% CI  0.05-2.28, P  0.27). CONCLUSIONS:
This meta-analysis demonstrates that the effectiveness of biomaterials and con-
servative treatment was not different. The biomaterials in comparison to other
interventional therapies did not show any difference in regard to effectiveness and
also incontinence rate.
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FROM GERD/HYPERACIDITY SYMPTOMS
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OBJECTIVES: Symptoms of gastro-oesophageal reflux disease are estimated to
occur in 30-50% of pregnancies, with the incidence approaching 80% in some
populations. Indian studies have shown prevalence ranging upto 50 % . As with
many other conditions in pregnancy, medical therapy with pharmaceutical
agents is a concern, as the potential teratogenicity of medications is not well
known. Though prevalence numbers are high, many patients have mild and
infrequent symptoms, which often respond to lifestyle and dietary modifica-
tions. However, some patients report very severe symptoms of hyperacidity
affecting their Quality of Life which need treatment. The safety of H2 Receptor
antagonists and PPIs in pregnancy is not well established. Antacids could be a
good option as their systemic toxicity is low and safety profile is enhanced.
METHODS: Data has been collected from practicing gynaecologists in a hospital
located in Southern India . 50 female patients suffering from heartburn and/or
dyspepsia as symptoms of hyperacidity and GERD were treated with antacids
containing aluminium hydroxide, magnesium hydroxide and dimethicone. The
patients were prescribed antacids for atleast 7 days and the effectiveness and
safety profile of antacids was studied. The patients were followed up after one
week and the response along with adverse effects were documented. RESULTS:
The effectiveness was achieved in 85 % of women who took only antacids atleast
for 1 week. In 10 % of patients, Proton Pump Inhibitor was also added to achieve
the desired response. Apart from 2 cases of mild diarrhea, no other significant
side effects were noted. CONCLUSIONS: Antacids containing aluminium hy-
droxide , magnesium hydroxide and dimethicone can be a good therapy option
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